Innate Pharma Announces Conference Call and Webcast for Third Quarter 2024 Results and Business Updates
Innate Pharma (Nasdaq: IPHA) has announced a conference call and webcast scheduled for Wednesday, November 13, 2024, at 2 p.m. CET / 8 a.m. ET to discuss third quarter 2024 results and business updates. Key executives participating include CEO Jonathan Dickinson, CMO Sonia Quaratino, COO Yannis Morel, CFO Frédéric Lombard, and EVP US Operations Arvind Sood. The live webcast will be accessible via a dedicated link, with a telephone option available for participants. A replay will be available on the company website for 90 days after the event.
Innate Pharma (Nasdaq: IPHA) ha annunciato una conferenza telefonica e una trasmissione in webcast programmata per mercoledì 13 novembre 2024, alle 14:00 CET / 8:00 ET per discutere i risultati del terzo trimestre 2024 e aggiornamenti aziendali. Saranno presenti i principali dirigenti, tra cui il CEO Jonathan Dickinson, il CMO Sonia Quaratino, il COO Yannis Morel, il CFO Frédéric Lombard e l'EVP delle operazioni negli Stati Uniti Arvind Sood. Il webcast sarà accessibile tramite un link dedicato, con un'opzione telefonica disponibile per i partecipanti. Una registrazione sarà disponibile sul sito web dell'azienda per 90 giorni dopo l'evento.
Innate Pharma (Nasdaq: IPHA) ha anunciado una conferencia telefónica y un webcast programado para miércoles 13 de noviembre de 2024, a las 2 p.m. CET / 8 a.m. ET para discutir los resultados del tercer trimestre de 2024 y las actualizaciones comerciales. Los ejecutivos clave que participarán incluyen al CEO Jonathan Dickinson, la CMO Sonia Quaratino, el COO Yannis Morel, el CFO Frédéric Lombard y el EVP de Operaciones en EE. UU., Arvind Sood. El webcast en vivo será accesible a través de un enlace dedicado, con la opción de teléfono disponible para los participantes. Una grabación estará disponible en el sitio web de la empresa durante 90 días después del evento.
인네이트 제약(상장 코드: IPHA)은 2024년 11월 13일 수요일 오후 2시 CET / 오전 8시 ET에 2024년 3분기 실적 및 비즈니스 업데이트를 논의하기 위한 컨퍼런스 콜 및 웹캐스트를 예정했다고 발표했습니다. 참석하는 주요 경영진으로는 CEO 조나단 디킨슨, CMO 소냐 쿼라티노, COO 야니스 모렐, CFO 프레데리크 롬바르, 미국 운영 EVP 아르빈드 수드가 있습니다. 실시간 웹캐스트는 전용 링크를 통해 접근 가능하며, 참가자들을 위한 전화 옵션도 제공됩니다. 이벤트 후 90일 동안 회사 웹사이트에서 재방송을 시청할 수 있습니다.
Innate Pharma (Nasdaq: IPHA) a annoncé une conférence téléphonique et un webcast programmés pour mercredi 13 novembre 2024, à 14h CET / 8h ET afin de discuter des résultats du troisième trimestre 2024 et des mises à jour commerciales. Les principaux dirigeants participants incluent le PDG Jonathan Dickinson, la CMO Sonia Quaratino, le COO Yannis Morel, le CFO Frédéric Lombard et l'EVP des opérations aux États-Unis, Arvind Sood. Le webcast en direct sera accessible via un lien dédié, avec une option téléphonique disponible pour les participants. Un enregistrement sera disponible sur le site web de l'entreprise pendant 90 jours après l'événement.
Innate Pharma (Nasdaq: IPHA) hat eine Telefonkonferenz und einen Webcast für Mittwoch, den 13. November 2024, um 14:00 Uhr CET / 8:00 Uhr ET angekündigt, um die Ergebnisse des dritten Quartals 2024 und Unternehmensupdates zu besprechen. Zu den teilnehmenden Führungskräften gehören CEO Jonathan Dickinson, CMO Sonia Quaratino, COO Yannis Morel, CFO Frédéric Lombard und EVP US-Operationen Arvind Sood. Der Live-Webcast wird über einen speziellen Link zugänglich sein, und es wird auch eine Telefonoption für die Teilnehmer angeboten. Eine Aufzeichnung wird für 90 Tage nach der Veranstaltung auf der Unternehmenswebsite verfügbar sein.
- None.
- None.
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that the Company will hold a conference call on Wednesday, November 13, 2024, at 2 p.m. CET / 8 a.m. ET, to give an update on business progress during the third quarter of 2024.
Participants during the call will be:
- Jonathan Dickinson, Chief Executive Officer
- Sonia Quaratino, Executive Vice President, Chief Medical Officer
- Yannis Morel, Executive Vice President, Chief Operating Officer
- Frédéric Lombard, Senior Vice President, Chief Financial Officer
- Arvind Sood, Executive Vice President, President of US Operations
Details for the Virtual Event
The live webcast will be available at the following link:
https://events.q4inc.com/attendee/381945831
Participants may also join via telephone using the following registration link: https://registrations.events/direct/Q4I280043
This information can also be found on the Investors section of the Innate Pharma website, www.innate-pharma.com. A replay of the webcast will be available on the Company website for 90 days following the event.
About Innate Pharma
Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Its innovative approach aims to harness the innate immune system through three therapeutic approaches: monoclonal antibodies, multi-specific NK Cell Engagers via its ANKET® (Antibody-based NK cell Engager Therapeutics) proprietary platform and Antibody Drug Conjugates (ADC).
Innate’s portfolio includes lead proprietary program lacutamab, developed in advanced form of cutaneous T cell lymphomas and peripheral T cell lymphomas, monalizumab developed with AstraZeneca in non-small cell lung cancer, several ANKET® drug candidates to address multiple tumor types as well as IPH4502 a differentiated ADC in development in solid tumors.
Innate Pharma is a trusted partner to biopharmaceutical companies such as Sanofi and AstraZeneca, as well as leading research institutions, to accelerate innovation, research and development for the benefit of patients.
Headquartered in
Learn more about Innate Pharma at www.innate-pharma.com and follow us on LinkedIn and X.
Information about Innate Pharma shares
ISIN code
|
FR0010331421 Euronext: IPH Nasdaq: IPHA 9695002Y8420ZB8HJE29 |
Disclaimer on forward-looking information and risk factors
This press release contains certain forward-looking statements, including those within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995. The use of certain words, including “anticipate,” “believe,” “can,” “could,” “estimate,” “expect,” “may,” “might,” “potential,” “expect” “should,” “will,” or the negative of these and similar expressions, is intended to identify forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, progression of and results from its ongoing and planned clinical trials and preclinical studies, review and approvals by regulatory authorities of its product candidates, the Company’s reliance on third parties to manufacture its product candidates, the Company’s commercialization efforts and the Company’s continued ability to raise capital to fund its development. For an additional discussion of risks and uncertainties, which could cause the Company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors (“Facteurs de Risque") section of the Universal Registration Document filed with the French Financial Markets Authority (“AMF”), which is available on the AMF website http://www.amf-france.org or on Innate Pharma’s website www.innate-pharma.com, and public filings and reports filed with the
In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by the Company or any other person that the Company will achieve its objectives and plans in any specified time frame or at all. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241106533289/en/
For additional information, please contact:
Investors
Innate Pharma
Henry Wheeler
Tel.: +33 (0)4 84 90 32 88
Henry.wheeler@innate-pharma.fr
Media Relations
NewCap
Arthur Rouillé
Tel.: +33 (0)1 44 71 00 15
innate@newcap.eu
Source: Innate Pharma SA
FAQ
When is Innate Pharma (IPHA) hosting its Q3 2024 earnings call?
Who are the key executives participating in Innate Pharma's (IPHA) Q3 2024 earnings call?